Cilostazol Production Cost Reports

The report provides detailed analysis essential for establishing a cilostazol production plant. It encompasses all critical aspects necessary for cilostazol production, including the cost of cilostazol production, cilostazol plant cost, cilostazol production costs, and the overall cilostazol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a cilostazol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Cilostazol Market Analysis: Demand and Supply Analysis, and Sourcing

Cilostazol is a quinolinone derivative that inhibits phosphodiesterase 3, helping widen blood vessels and reduce platelet aggregation. It was developed by Otsuka and marketed under the brand name Pletal. Its approved use is to improve walking distance in patients with intermittent claudication caused by peripheral arterial disease. Demand comes from hospitals, vascular clinics, cardiology practices, and retail pharmacies. As an established generic medicine, cilostazol benefits from widespread registrations and relatively low production costs. Treatment outcomes are assessed through walking distance, symptom improvement, and platelet aggregation.

Cilostazol demand and supply analysis depends on active pharmaceutical ingredient (API) manufacturers, generic drug producers, and distribution networks. Otsuka supplies the originator product, while companies such as Teva, Apotex, Mylan, and Hikma have marketed generic tablets in various markets. Manufacturers in India and China contribute significantly to API supply, while qualified suppliers provide high-purity material for pharmaceutical production. Demand and supply depend on the prevalence of peripheral arterial disease, prescribing practices, generic pricing, and the cost of tetrazole intermediates. Regulatory filings, tablet registrations, contract manufacturing agreements, and supplier qualification requirements also influence sourcing. Most tablet manufacturers purchase the API from specialized producers rather than manufacture it in-house.

Cilostazol demand is driven by the long-term treatment of peripheral arterial disease, with patient numbers influenced by aging populations, diabetes, and smoking rates. The standard dosage is 100 mg twice daily, equivalent to approximately 73 g of API per patient annually. Buyers evaluate price, purity & impurity profiles, dissolution performance, regulatory compliance, and supply reliability. API specifications commonly cover residual solvents, isomer content, particle size, and polymorphic form. Demand also depends on diagnosis rates, treatment duration, patient adherence, prescriber decisions, and generic competition. The drug's contraindication in patients with heart failure limits its eligible patient population and affects overall market demand.

Summary of the Product, Grades, and Uses

Cilostazol is a pharmaceutical active ingredient with CAS number 73963-72-1, molecular formula C20H27N5O2, and molecular weight of 369.46 g/mol. The chemical name of the compound is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone. Its elemental composition is 65.02% carbon, 7.37% hydrogen, 18.96% nitrogen, and 8.66% oxygen. The compound melts between 159.4 degree Celsius and 160.3 degree Celsius, and can crystallize from methanol as colorless needles. Product quality is assessed through assay, related substances & residual solvents, water content, and physical appearance. These parameters help ensure consistent quality for pharmaceutical manufacturing.

Cilostazol is practically insoluble in water, ether, 0.1 N hydrochloric acid, and 0.1 N sodium hydroxide. It dissolves readily in acetic acid, chloroform, N-methyl-2-pyrrolidone, and dimethyl sulfoxide. Its low water solubility makes particle size and dissolution performance important during tablet formulation. Manufacturers control particle size, surface area, and wetting properties to support consistent drug release. Milling methods, surfactant selection, disintegrant levels, and compression force can affect dissolution behavior. These formulation parameters are evaluated during development and quality control to ensure that the finished tablets meet the required specifications.

Cilostazol is marketed as conventional tablets in 50 mg and 100 mg strengths. The 50 mg tablets are triangular, while the 100 mg tablets are round. Common excipients include carboxymethylcellulose calcium, corn starch, hypromellose 2910, magnesium stearate, and microcrystalline cellulose. The active pharmaceutical ingredient is supplied according to applicable pharmacopeial standards & regulatory specifications rather than separate commercial grades. Reference standards, isotope-labeled compounds, and specific impurity markers are available for analytical testing. Finished tablets are packaged in blisters or bottles, with desiccants, cartons, and patient information leaflets used as required.

Main End-Uses of Cilostazol

Cilostazol is prescribed to relieve the symptoms of intermittent claudication. The recommended dose is 100 milligrams twice daily, taken at least half an hour before or two hours after breakfast and dinner. Meal timing is important because a fatty meal can significantly increase absorption. Treatment effectiveness is assessed by measuring walking distance rather than using laboratory markers. Benefits usually appear after four to twelve weeks of consistent dosing. Walking distance is measured on a treadmill before and after treatment. Age, diabetes, smoking, lipid levels, and blood pressure are important factors underlying the disease.

The cilostazol dose is reduced to 50 milligrams twice daily when it is taken with certain enzyme inhibitors. Ketoconazole, itraconazole, erythromycin, and diltiazem inhibit the main enzyme responsible for its clearance. Ticlopidine, fluconazole, and omeprazole inhibit the secondary enzyme. Cilostazol is metabolized mainly by cytochrome P450 3A4 and, to a lesser extent, by 2C19. Its dehydro metabolite is four to seven times as active as the parent drug, while its hydroxy metabolite has about one fifth of the parent drug's activity. Grapefruit juice increases drug exposure through the same enzyme pathway and is therefore discouraged. This is particularly relevant because patients often take the tablet around breakfast. Antiplatelet agents, anticoagulants, enzyme inhibitors, and cardiac medications should all be reviewed before treatment begins.

Cilostazol has predictable pharmacokinetics that support a simple twice-daily dosing schedule. The apparent elimination half-lives of the parent drug and both active metabolites range from 11 to 13 hours. Repeated dosing results in about twofold accumulation, with steady state reached within a few days. Protein binding ranges from 95% to 98%, mainly to albumin. About 74% of a dose is excreted in urine and 20% in feces, with no unchanged drug detected in urine. Approximately 30% of the dose appears in urine as the hydroxy metabolite. Absorption, distribution, metabolism, excretion, and protein binding remain predictable across the dosing range. This predictability is one reason the twice-daily dosing schedule has not required revision.

Cilostazol Market Risks

Cilostazol has a key contraindication that limits its commercial potential. It must not be used in patients with heart failure of any severity because phosphodiesterase three inhibitors have been associated with reduced survival in advanced heart failure. Peripheral arterial disease and heart failure often occur together in older patients. Headache, diarrhea, palpitations, and dizziness also lead some patients to discontinue treatment. As a result, prescribers carefully screen patients before starting therapy, keeping the treated population well below the number of diagnosed patients. Heart failure screening, blood pressure checks, heart rhythm reviews, and tolerance assessments are performed before prescribing. This contraindication is absolute, not a matter of clinical judgment, and excludes many older patients who might otherwise qualify for treatment.

Cilostazol manufacturers face the challenges of producing an established oral generic drug. Tablets sell at commodity prices, and many suppliers are qualified to produce the active ingredient. The tetrazole intermediate is a more expensive and difficult input to source than the quinolinone. Supervised exercise programs and revascularization also compete for the same patient population. New suppliers face established regulatory filings, lengthy customer qualification processes, and thin profit margins. Profitability depends on tablet prices, active ingredient costs, tender terms & freight, and batch release testing. New entrants must compete with established suppliers whose development costs have long since been recovered.

Cilostazol Production Process and Main Cost Drivers

The cilostazol production process runs from 6-hydroxy-3,4-dihydroquinolinone and 1-cyclohexyl-5-chlorobutyl tetrazole through base-mediated etherification, crystallization, filtration, washing, recrystallization, drying, milling, and tableting.

1. By Williamson Etherification of 6-Hydroxy-3,4-Dihydroquinolinone with 1-Cyclohexyl-5-Chlorobutyl Tetrazole: The main inputs are 6-hydroxy-3,4-dihydroquinolinone, 1-cyclohexyl-5-chlorobutyl tetrazole, potassium hydroxide, potassium carbonate, sodium sulfite, n-butanol or 1-propanol, ethyl acetate, toluene, and purified water.

Cilostazol synthesis joins two prepared fragments in a single bond-forming step. The phenol of 6-hydroxy-3,4-dihydroquinolinone is deprotonated and alkylated by the chlorobutyl tetrazole. Charging, reaction, cooling, filtration & washing, and drying follow one another in order. One route refluxes the pair in n-butanol over potassium hydroxide and potassium carbonate for about five hours, giving roughly 85% crude. A phase transfer version runs sodium hydroxide in water against toluene with a quaternary ammonium catalyst, reaching 88% crude at 99% purity. A purely aqueous version uses water at three to seven times the quinolinone weight, with alkali carbonate, a little hydroxide, and sodium sulfite against coloration. Base strength, water content, molar ratio & temperature, and addition order govern the coupling. Excess hydroxide attacks the tetrazole faster than it speeds the alkylation.

Cilostazol purity is won in the finish rather than in the coupling. The aqueous route holds 85 to 92 degrees Celsius for about six hours and runs a continuous disperser to stop the crystals from agglomerating. Yields on that route run near 89 to 92 percent at 99.4 to 99.7 percent purity. A 1-propanol and water route with hydrated potassium hydroxide refluxes for seven to eight hours, then cools below 15 degrees Celsius to drop the crude. An ethyl acetate slurry, or recrystallization from 1-propanol at about pH 11, lifts purity to 99.9 percent with the bis-tetrazole impurity below 0.1 percent. Acetone, toluene, methyl ethyl ketone, ethyl acetate, methanol, and acetonitrile all appear as recrystallization solvents. Crystal habit, agglomeration & filtration rate, wash volume, and drying temperature all affect recovery. Each additional purification step improves purity but reduces yield, which is why process chemists focus more on the number of crystallization steps than on the coupling reaction.

Main Factors Affecting Cilostazol Production Cost

Cilostazol production costs begin with the tetrazole fragment. 1-Cyclohexyl-5-chlorobutyl tetrazole is expensive to produce and unstable in the presence of hydroxide, so excess base can destroy it. The molar ratio, base strength, water content, temperature, and order of addition directly affect the yield. The quinolinone fragment is less expensive and is often added in a slight excess to protect the tetrazole. Solvent selection, washing volumes & filtration time, drying, and milling account for the remaining conversion costs. Fragment prices, molar ratios, base costs, solvent volumes, and recovery credits determine material costs. The quinolinone part of the molecule involves standard heterocyclic chemistry, while the molar ratio is the most important factor.

Cilostazol production economics depend mainly on yield and impurity control rather than specialized equipment. Manufacturers must remove unreacted starting materials, the lactam nitrogen-alkylated isomer, tetrazole elimination products, and bis-tetrazole dimers. Each recrystallization reduces yield and adds solvent costs and processing time. Tablet production costs arise mainly from downstream operations such as granulation, compression, coating, and packaging. Micronization adds another step because the dissolution of this poorly soluble drug depends on particle surface area. Isomer content, dimer content, residual solvents, water content, and color determine whether a batch requires rework. A batch that fails dissolution testing after milling may sometimes be reworked rather than discarded, although the additional processing uses press time that the plant had already allocated to other production.

Raw Materials for Cilostazol Production Plant and its Procurement

Cilostazol raw material procurement involves a small number of specialized materials, with most attention focused on one key intermediate. Chlorobutyl tetrazole is sourced from fine chemical manufacturers that handle azide chemistry under containment. The second main input, 6-hydroxy-3,4-dihydroquinolinone, is widely available from Indian and Chinese suppliers. Potassium hydroxide, potassium carbonate, sodium sulfite, and quaternary ammonium catalysts complete the reaction inputs. Specifications cover purity, moisture, color, residual solvents, and heavy metal limits. Supplier qualification depends on audits, regulatory filing support, impurity data, stability data, and delivery performance. Qualifying a second source for the tetrazole intermediate usually takes nearly a year.

Cilostazol manufacturers also procure solvents and tablet excipients. n-Butanol, 1-propanol, toluene, ethyl acetate, acetone, and methanol are used in reactions and purification. The finished tablets contain carboxymethylcellulose calcium, corn starch, hypromellose, magnesium stearate, and microcrystalline cellulose. Packaging materials include blisters, bottles, desiccants, cartons, and leaflets. Buyers maintain safety stock of the tetrazole intermediate rather than solvents, which are generally readily available. Solvent acceptance specifications cover grade, water content, peroxide levels, color, and residue on evaporation. Recovered solvents must be requalified before reuse in a regulated production step.

Sustainability and Regulatory Requirements

Cilostazol manufacture runs under pharmaceutical good manufacturing practice across two separate operations. Active ingredient production follows the drug master file, with specifications covering assay, related substances, residual solvents, and elemental impurities. Tablet manufacture adds blend uniformity, content uniformity, hardness, friability, and dissolution testing. Dissolution is the critical release test, since the molecule is practically insoluble in water. Any change to either operation reopens its own regulatory file. Drug master files, site inspections, validation batches, stability data, and change control support every filing. Dissolution profiles are compared against the reference product in any generic submission.

Cilostazol chemistry carries a genuine upstream process safety burden. Tetrazole rings are built with azide reagents, which form explosive metal azides and release hydrazoic acid on acidification. Suppliers therefore run dedicated equipment, strict pH control, blast protection, and tight waste handling. Spent mother liquors, alcohol washes, and toluene streams are recovered where volumes justify a column. Aqueous liquors carrying potassium salts and sulfite go to effluent treatment, and residues are incinerated. Azide inventory, pH control, blast protection, waste quench, and operator training all cost money. That burden is why the fragment is usually bought rather than made, and it leaves the margin on the hardest part of the molecule with a few specialist suppliers.

CAPEX & OPEX for a Cilostazol Production Plant

Cilostazol plant setup costs are divided between the synthesis area and the oral solid dosage area. The synthesis section requires glass-lined or stainless steel reactors, condensers, crystallizers, centrifuges or filter dryers, solvent recovery systems, vacuum dryers, and milling equipment. The tableting section needs dispensing booths, granulators, fluid bed dryers, blenders, tablet compression machines, coating pans, and blister packaging lines. Quality control requires chromatography systems, dissolution baths, particle size analyzers, residual solvent testing capabilities, and stability chambers. Although an oral solid dosage facility is less expensive to build than a sterile manufacturing line, it still requires full qualification. Reactors, crystallizers & filter dryers, mills, tablet presses, and blister lines form the core equipment across the two sections. Qualification, validation, and documentation costs often exceed the equipment costs themselves.

Cilostazol operating costs are driven mainly by raw materials during active ingredient production and by labor during tablet manufacturing. The tetrazole intermediate alone can account for most of the drug substance material cost. Utilities include steam, chilled water, cooling water, nitrogen, compressed air, and purified water. Labor costs cover reactor operators, dispensing staff, compression and packaging crews, analysts, and quality assurance personnel. Solvent recovery rates, cycle time, batch size, yield, and rejection rates determine the cost per kilogram. Steam, cooling water, chilled water, nitrogen, compressed air, and purified water are required continuously. Reactor hours and tablet press hours are the main capacity constraints in both sections, and their utilization rarely stays balanced throughout a production campaign.

Plant Location and Investment Factors

Cilostazol production relies on standard pharmaceutical manufacturing capabilities rather than specialized feedstocks. India has large-scale active ingredient and tablet manufacturing capacity, with filings in regulated markets. China supplies intermediates and active ingredients through established heterocyclic chemistry plants. Japan retains the originator operation, while Israel specializes in process chemistry. North American and European tablet manufacturers generally purchase the active ingredient instead of producing it themselves. Site selection depends on regulatory history, inspection records, labor costs, solvent handling, and effluent treatment capacity. A facility already approved for oral solid dosage manufacturing can add cilostazol production without constructing new buildings.

Cilostazol investment decisions depend on whether the owner plans to manufacture the active ingredient or the finished tablet. Producing the tetrazole fragment in-house changes the cost structure but requires on-site azide handling. Purchasing the fragment simplifies plant operations but leaves the associated margin with the supplier. Entering regulated markets requires stability data & validation batches, and an inspection history before the first sale. New entrants must compete with products that have had regulatory filings in place for many years. Profitability depends on the make-or-buy decision, strength mix, batch size & filing strategy, and customer base. Most owners choose to purchase the fragment and perform the coupling step in-house, as few manufacture the fragment themselves.

Major Cilostazol Producing Regions

Cilostazol production concentrates in India, China, Japan, and Israel. India supplies both active ingredient and finished tablets, with several plants holding filings in regulated markets. China contributes active ingredient and the heterocyclic intermediates behind it. Japan holds Otsuka, which developed the molecule and still sells the originator brand. Israel holds Wavelength Pharmaceuticals, which carries process chemistry on the high-purity grade. North America and Europe hold tablet operations at Teva, Apotex, Mylan, and Hikma that draw on those sources. Intermediate supply, active ingredient capacity, tablet capacity, and regulatory filings are spread across those countries. Most finished tablets sold in Western markets now originate from Asian drug substance.

Key Cilostazol Producers

Otsuka Pharmaceutical

• Japanese pharmaceutical company that developed the molecule under the code OPC-13013.
• Markets the originator tablet as Pletal in 50 and 100 milligram strengths.
• Competes on originator data, prescriber familiarity, quality record, and global reach.
• Holds the reference product against which generic filings are measured.

Teva Pharmaceuticals

• Generic manufacturer holding tablet registrations in the American market.
• Owns process chemistry covering phase transfer and butanol routes to the molecule.
• Competes on scale, filing coverage, cost base, and distribution depth.
• Supplies 50 and 100 milligram tablets under its own labeler codes.

Apotex

• Canadian generic manufacturer supplying cilostazol tablets in North America.
• Runs large oral solid dosage capacity across several sites.
• Competes on cost base, formulation capability, breadth, and delivery record.
• Serves retail and institutional pharmacy channels with the finished tablet.

Mylan

• American generic business, now within Viatris, listed among cilostazol tablet suppliers.
• Draws on oral solid dosage plants in the United States and India.
• Competes on scale, procurement strength, channel access, and regulatory record.
• Supplies the tablet to retail, hospital, and institutional accounts.

Hikma Pharmaceuticals

• Generic group that has supplied cilostazol tablets through its West-Ward operation.
• Operates oral solid dosage capacity across American, European, and Middle Eastern sites.
• Competes on regional manufacturing, portfolio breadth, service, and supply assurance.
• Serves hospital and retail customers from those plants.

Wavelength Pharmaceuticals

• Israeli active ingredient maker, formerly Chemagis, with fine chemical capability.
• Holds process chemistry delivering 99.9% purity with controlled bis-tetrazole content.
• Competes on purity, impurity control, documentation, and inspection records.
• Supplies formulators that need a tightly specified drug substance.